CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: March 14 at 7:05:25 p.m. EDT Loading Chart for MRSN ...

NASDAQ:MRSN opened at $0.53 on Thursday. The stock has a market cap of $64.88 million, a P/E ratio of -0.86 and a beta of 1.39. The stock has a 50 day simple moving average of $0.77 and a 200 day ...

Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...